Considerations for Using Venixxa in Patients with Congestive Heart Failure

Current Guideline-Based Therapy for CHF

The European Society of Cardiology recommends ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) plus beta-blockers as first-line therapy for symptomatic patients with heart failure with reduced ejection fraction (HFrEF) to reduce mortality and hospitalization 1, 2
The European Society of Cardiology suggests mineralocorticoid receptor antagonists (MRAs) like spironolactone for patients who remain symptomatic despite treatment with ACE inhibitors and beta-blockers 1, 2
The European Society of Cardiology recommends diuretics for symptom relief in patients with signs of congestion 1, 2
The European Society of Cardiology recommends sacubitril/valsartan as a replacement for ACE inhibitors in patients who remain symptomatic despite optimal treatment 1, 2

The European Society of Cardiology advises against calcium channel blockers like diltiazem and verapamil as they increase the risk of heart failure worsening and hospitalization 1, 2
The European Society of Cardiology recommends avoiding NSAIDs and COX-2 inhibitors as they increase the risk of heart failure worsening 1
The American College of Cardiology does not recommend routine use of nutritional supplements (coenzyme Q10, carnitine, taurine, and antioxidants) or hormonal therapies 3, 4
The European Society of Cardiology advises against the addition of an ARB or renin inhibitor to the combination of an ACE inhibitor and MRA due to increased risk of renal dysfunction and hyperkalemia 1, 2

The American College of Cardiology notes that potential for fluid retention can worsen CHF symptoms 3, 5
The European Society of Cardiology highlights the risk of electrolyte disturbances, particularly hyperkalemia 6, 7
The European Society of Cardiology recommends considering potential drug interactions with established CHF medications 6, 7
The European Society of Cardiology advises evaluating the effect on blood pressure, as hypotension can limit the use of guideline-directed therapies 6, 7

The European Society of Cardiology recommends determining if the medication is included in evidence-based guidelines for CHF management 1, 2
The European Society of Cardiology suggests assessing if the medication belongs to a class specifically contraindicated in CHF 1, 2
The American College of Cardiology recommends evaluating potential effects on fluid balance 3, 5
The European Society of Cardiology advises evaluating potential effects on renal function, electrolyte balance, and hemodynamics (blood pressure, heart rate) 6, 7
The European Society of Cardiology recommends considering potential drug interactions with established CHF therapies 6, 7
The European Society of Cardiology suggests weighing benefits against risks, prioritizing mortality and morbidity reduction 1, 2